1 / 1

SCH 900518 Tablet Study Diagram (Phase 2)

SCH 900518 Tablet Study Diagram (Phase 2). If <LLQ at TW12 36 wks PegIntron/RBV*. Arm 1. PegIntron + Ribavirin Control. If >LLQ at TW12 12 wks 400 mg SCH 900518 + RTV QD + PegIntron + Ribavirin (Total 48 wks). 200 mg SCH 900518 + 100 mg Ritonavir QD PegIntron + Ribavirin. Arm 2.

vivek
Download Presentation

SCH 900518 Tablet Study Diagram (Phase 2)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SCH 900518 Tablet Study Diagram (Phase 2) If <LLQ at TW12 36 wks PegIntron/RBV* Arm 1 PegIntron + Ribavirin Control If >LLQ at TW12 12 wks 400 mg SCH 900518 + RTV QD + PegIntron + Ribavirin (Total 48 wks) 200 mg SCH 900518 + 100 mg Ritonavir QD PegIntron + Ribavirin Arm 2 400 mg SCH 900518 + 100 mg Ritonavir QD PegIntron + Ribavirin Arm 3 If <LLQ at 4 wks 12 weeks of PegIntron/RBV 4 Weeks PegIntron/RBV 200 mg SCH 900518 + 100 mg Ritonavir QD PegIntron + Ribavirin Arm 4 400 mg SCH 900518 + 100 mg Ritonavir QD PegIntron + Ribavirin 4 Weeks PegIntron/RBV Arm 5 If ≥LLQ at 4 wks 36 weeks of PegIntron/RBV 100 mg SCH 900518 + 100 mg Ritonavir BID PegIntron + Ribavirin Arm 6 4 Weeks PegIntron/RBV 600 mg SCH 900518 + 100 mg Ritonavir QD PegIntron + Ribavirin Arm 7 Lead-in 12 Weeks *If <1 log drop from baseline at 12 weeks, D/C therapy

More Related